Target/Product
Primary Focus
Research
Preclinical (CTA/ IND enabling)
Clinical (Phase 1)
Milestone Date

Monotherapy in solid tumour (colorectal, pancreatic, biliary cancer) followed by combination with anti-PD-1/PD-L1

Phase 1 mono safety completion
& start of Phase 2 mono expansion – H1 20
Phase 1 combo with anti-PD-1/PD-L1 safety completion – H1 21

Preclinical development candidate – H2 19
Clinic ready – H2 20

Research

Partnered pan-RAF inhibitor programme (ongoing milestones)

Target/Product
Primary Focus
Milestone Date

Monotherapy in solid tumour (colorectal, pancreatic, biliary cancer) followed by combination with anti-PD-1/PD-L1

Phase 1 mono safety completion
& start of Phase 2 mono expansion – H1 20
Phase 1 combo with anti-PD-1/PD-L1 safety completion – H1 21

Research
Pre-clinical (CTA/ IND enabling)
Clinical (Phase 1)
Target/Product
Primary Focus
Milestone Date

Clinic ready – H2 20

Research
Pre-clinical (CTA/ IND enabling)
Clinical (Phase 1)
Target/Product
Primary Focus
Milestone Date

Preclinical development candidate – H2 19
Clinic ready – H2 20

Research
Pre-clinical (CTA/ IND enabling)
Clinical (Phase 1)
Target/Product
Primary Focus
Milestone Date

Partnering Candidate

Research
Pre-clinical (CTA/ IND enabling)
Clinical (Phase 1)
Target/Product
Primary Focus
Milestone Date

Research

Partnered pan-RAF inhibitor programme (ongoing milestones)

Research
Pre-clinical (CTA/ IND enabling)
Clinical (Phase 1)